Impairment of health‐related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
AbstractBackgroundChildren treated for acute lymphoblastic leukemia (ALL) receive prolonged treatment, resulting in toxicities that affect health‐related quality of life (HR‐QoL). Longitudinal assessment of HR‐QoL allows improved understanding of experiences with ALL.ProcedureParent‐proxy and child self‐report HR‐QoL over the first year of chemotherapy were evaluated in the context of DFCI Protocol 05‐001, a phase 3 therapeutic trial for childhood ALL. HR‐QoL was assessed with the Pediatric Quality‐of‐Life inventory (PedsQL) domains for Pain and Hurt, Procedural Anxiety, Treatment Anxiety, Emotional Functioning, General Fatigue, and Sleep/Rest Fatigue.ResultsTotal of 281 subjects participated, with 141 contributing at least one child report and 280 at least one parent report. Children with ALL experienced impairment in HR‐QoL by both patient and parent report compared to the published PedsQL reference population at each time point on each subscale. Agreement between parent and child assessment of HR‐QoL impairment was high, particularly among those for whom HR‐QoL was not impaired. During the consolidation phase, which included intensive asparaginase administration, multivariable models demonstrated more impairment in Treatment Anxiety and Procedural Anxiety for children treated with intramuscular asparaginase than intravenous asparaginase, but randomized groups were otherwise similar in HR‐QoL. Impairments in fatigue, both General and Sleep/Rest, were evident throughout and worse during intensive asparaginase therapy.ConclusionsThis report examines HR‐QoL for children with ALL during treatment longitudinally by parent and patient report across multiple domains. Children with ALL demonstrated substantial impairment in HR‐QoL, particularly related to fatigue during intensive consolidation therapy including asparaginase.
